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A B S T R A C T

Background: Genetic factors that inﬂuence kidney traits have been understudied for low frequency and
ancestry-speciﬁc variants.
Methods: We combined whole genome sequencing (WGS) data from 23,732 participants from 10 NHLBI
Trans-Omics for Precision Medicine (TOPMed) Program multi-ethnic studies to identify novel loci for estimated glomerular ﬁltration rate (eGFR). Participants included European, African, East Asian, and Hispanic
ancestries. We applied linear mixed models using a genetic relationship matrix estimated from the WGS
data and adjusted for age, sex, study, and ethnicity.
Findings: When testing single variants, we identiﬁed three novel loci driven by low frequency variants more
commonly observed in non-European ancestry (PRKAA2, rs180996919, minor allele frequency [MAF] 0.04%,
P = 6.1 £ 1011; METTL8, rs116951054, MAF 0.09%, P = 4.5 £ 109; and MATK, rs539182790, MAF 0.05%,
P = 3.4 £ 109). We also replicated two known loci for common variants (rs2461702, MAF=0.49,
P = 1.2 £ 109, nearest gene GATM, and rs71147340, MAF=0.34, P = 3.3 £ 109, CDK12). Testing aggregated
variants within a gene identiﬁed the MAF gene. A statistical approach based on local ancestry helped to identify replication samples for ancestry-speciﬁc variants.
Interpretation: This study highlights challenges in studying variants inﬂuencing kidney traits that are low frequency in populations and more common in non-European ancestry.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
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Research in Context
Evidence before this study
Several loci have been identiﬁed for estimated glomerular ﬁltration rate (eGFR) in genome-wide association studies. Genetic
factors that inﬂuence kidney traits have been understudied for
low frequency and ancestry-speciﬁc variants.
Added value of this study
The main ﬁndings of this study are the identiﬁcation of ancestry-speciﬁc rare variants associated with eGFR either individually or in aggregate units within a gene. We also showed the
utility of estimating ancestry-speciﬁc allele frequencies for rare
sequencing variants using local ancestry to identify ancestryrelated replication samples when using multi-ethnic studies.
This study also highlights challenges for the study of rare/low
frequency variants in multi-ethnic studies, including ﬁnding
suitable samples for replication of ancestry-speciﬁc variants.
Implications of all the available evidence
Rare and low frequency variants are more likely to be population-speciﬁc and their genetic contribution to eGFR variation is
mostly unknown. Our study provides important information
for future WGS studies of rare SNVs for kidney traits, with
implications for study design of variant discovery and replication, particularly when studying diverse ancestry populations.

1. Introduction
Reduced kidney function, assessed with the estimate glomerular
ﬁltration rate (eGFR), deﬁnes chronic kidney disease (CKD). Low
eGFR is associated with cardiovascular disease morbidity [1], mortality [2,3], poor quality of life and high health care costs for its treatment [4]. CKD has a high burden among non-European ethnic groups
[5]. In the U.S., the burden of CKD in African American is attributed in
part to the presence of ancestry-speciﬁc genetic variants, i.e., APOL1
high-risk genotypes [6]. Genetic factors and underlying pathways
inﬂuencing eGFR in populations can provide insights into CKD occurrence, mechanistic pathways, and downstream complications.
Genetic studies that included ethnically diverse populations have
yielded important gains in gene discovery and have advanced ﬁne mapping by leveraging differences in allele frequencies and in coinheritance
of genetic variants across ancestral groups [7,8]. In addition, substantial
evidence indicates that ancestry-speciﬁc genetic variants contribute to
CKD [6,9]. The current study expands on prior genetic studies of kidney
loci through interrogation of rare and low frequency variants from
whole genome sequencing (WGS) in the National Heart Lung and Blood
Institute’s Trans-Omics for Precision Medicine (TOPMed) program. We
aimed to understand a role of rare and low frequency variants that individually or in aggregate inﬂuence eGFR, and to identify ancestry-speciﬁc
genomic regions associated with eGFR in African Americans and Hispanics/Latinos through admixture mapping. Using a newly described
statistical approach based on local ancestry, we estimated ancestry-speciﬁc allele frequencies for rare sequencing variants and showed their
utility for identifying ancestry-related replication samples.
2. Methods
2.1. Ethics statement
All human research was approved by the relevant institutional
review boards and conducted according to the Declaration of Helsinki. All participants provided written informed consent.
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2.2. Study design and participants
The study included 23,732 participants from ten studies with phenotype data and WGS from the TOPMed Freeze 5b, for ﬁve racial/ethnic groups: European Americans, African Americans, East Asians,
Hispanic/Latinos, and Native Americans. We followed TOPMed guidelines when reporting race/ethnicity and ancestry (WEB Resources).
Admixture mapping analyses included a subset of 9,479 admixed
African Americans and Hispanics/Latinos. The following studies contributed data: Old Order Amish, Atherosclerosis Risk in Communities
(ARIC), Framingham Heart Study (FHS), Genetic Epidemiology Network of Arteriopathy (GENOA), Genetic Epidemiology Network of
Salt Sensitivity (GenSalt), Genetic Study of Atherosclerosis Risk (GeneSTAR), Hypertension Genetic Epidemiology Network (HyperGEN),
Jackson Heart Study (JHS), Multi-Ethnic Study of Atherosclerosis
(MESA) and Women’s Health Initiative (WHI). Demographic, clinical
data and kidney phenotypes were obtained from study clinical visits.

2.3. Phenotyping procedures
We performed centralised harmonization of the phenotype and
eGFR was calculate using the serum creatinine-based Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [10]. For
studies with serum creatinine assayed before 2009 using a Jaffe assay,
we multiplied the serum creatinine value to 0.95. The CKD-EPI eGFR
estimation uses a race term for black race to account for biological
variations in non-GFR determinants. This equation has been widely
used in both research and clinical care, although some concerns have
been raised related to race component of the equation [11]. To
account for differences in trait distribution by study and among ethnic groups, eGFR was inverse normalised within study and racial/ethnic groups and then rescaled to recover original trait variance [12].
Therefore, results are reported using units of ml/min/1.73 m2.

2.4. Whole genome sequencing data generation and quality control
Contributing studies had WGS from TOPMed Freeze 5b. WGS was
performed at an average depth of 38x using DNA from blood as previously reported4. Processing of whole genome sequences was
harmonised across genomic centres using a standard pipeline (see
URL in the Web Resources section). Brieﬂy, participants were
sequenced at the Broad Institute, the Northwest Genomic Center at
the University of Washington, and the New York Genome Center.
GeneSTAR samples were sequenced at Macrogen and Illumina. Central quality control and variant calling was performed jointly at the
University of Michigan Informatics Resource Center. Further quality
control that focused on sample identity was performed at the University of Washington Data Coordinating Center. All methods are
described on the dbGaP website at: https://goo.gl/ntuJbR. After site
level ﬁltering, TOPMed freeze 5b consisted of ~438 million single
nucleotide variants (SNVs) and ~33 million short insertion-deletion
(indel) variants. Most indels were singleton or rare, with only 12%
with allele frequency > 1%. Read mapping was done using the 1000
Genomes Project reference sequence versions for human genome
build GRCh38. Functional annotations were performed using the
WGSA Annotator [13], and WGSAParsr was used to generate simpliﬁed WGSA annotation ﬁles and variant grouping ﬁles for gene-based
aggregate tests (see URL in the Web Resources section). Principal
components (PC) of ancestry were estimated among all samples
using PC-Relate and PC-AiR [14, 15]. We used the Omics Analysis,
Search and Information System (OASIS) based on TOPMed data for
the included individuals to calculate linkage disequilibrium among
SNVs and to plot genomic regions (see URL in the Web Resources section).
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2.5. Statistical methods
2.5.1. Single variants association analysis and gene-based collapsing
analysis
Association analyses were performed in a cloud computing environment under DNAnexus [16] (see URL in the Web Resources section).
Single variant association test. We ﬁtted a linear mixed model
using covariates of age, sex, and categories of study, race/ethnicity,
and case-control status as needed. To account for genetic similarity
among subjects, we used the genetic relationship matrix estimated
from the WGS data from PC-Relate to specify the random effects
covariance structure. We allowed for heterogeneous residual variance components, and grouped subjects by study, race/ethnicity, and
case-control status. We used the Wald test for single variant association analyses of 43,622,178 autosomal variants ﬁltered for a minor
allele count > 10. The signiﬁcance threshold was p < 5.0 £ 109,
which has been determined to be the appropriate genome-wide
threshold for sequencing studies [17, 18]. We estimated the phenotypic variance explained (PVE) by each variant and their joint PVE
using methods described in Supplemental material. Although this
study is focused on rare and low frequency variants, we also examined the association of previously reported common variants at eGFR
loci (Genome Catalogue, see URL in the Web Resources section) and
the presence of secondary associations at the loci that were genomewide signiﬁcant in our single variant analyses using conditional analyses. The conditional analyses used the most signiﬁcant SNV in our
data as a covariate and examined if there were additional SNVs with
a p-value lower than the index SNV within a window of 1 Mbase of
the index SNV.
Gene-based association tests. For gene-based tests, variants were
aggregated by GENCODE genes (v24). Variants within a gene were ﬁltered to retain a set of rare variants (minor allele frequency [MAF] <
1%) that were predicted as loss-of-function variants (LoF), protein
altering small deletions/insertions (indels) or synonymous SNVs
which have a deleterious functional annotation (FATMM-MKL
score>0.5 or MetaSVM score > 0 for missense SNVs). Variants in a
5 kb window promoter region (upstream of transcription start site
[19] and in a FANTOM5 [Functional ANalyses Through Hidden Markov models] peak) [18] and variants at the ﬁrst intron of genes were
also included. Genes with at least 10 individuals with at least one
copy of any alternative allele were included. We performed both burden and SKAT tests and used a conservative signiﬁcance threshold of
p < 1.6 £ 106 based on Bonferroni correction for two tests on each
of 16,054 genes included in analyses. To identify the contribution of
one or more variants within genes with a gene-based signiﬁcant
association, we tested the association of each single variant within
the aggregate gene unit. We performed leave-one-variant-out analyses with variants aggregated within a gene for gene-based tests.
2.5.2. Admixture mapping
These analyses included only self-identiﬁed African American,
African Caribbean, or Hispanic/Latino TOPMed participants
(n = 20,048) of which 9,479 had eGFR data. The reference panel for
local ancestry inference included 37 African, 35 European, and 20
Native American individuals with phased sequence data available
from the Simons Genome Diversity Project (SGDP) [20]. After removing very low frequency variants (minor allele count < 2 in SGDP or <
5 in TOPMed), 9,137,968 autosomal SNVs remained for analysis. We
used the HapMap genetic map [21], lifted over to build 38, to estimate genetic positions for each variant, which was needed for inferring local ancestry and to estimate the signiﬁcance threshold using
Signiﬁcance Threshold Estimation for Admixture Mapping (STEAM).
The various maps are highly correlated at the scale that is relevant
for admixture mapping (Mbase) [22] and our prior studies have
shown no differences when comparing two different choices of

genetic maps for inferring local ancestry [23]. We inferred the number of alleles inherited from African, European, and Native American
ancestral populations for each admixed individual using RFMix (version 1.5.4) with a window size of 0.1 cM. Generations since admixture (6 for African American samples and 10 for Hispanic/Latino
samples) were chosen to reﬂect estimates from previous studies [24,
25]. To estimate admixture proportions for each individual, we calculated the genome-wide average local ancestry. We used an iterative
procedure to estimate kinship coefﬁcients adjusted for population
structure and admixture, which were used in our linear mixed model
to adjust for relatedness in admixture mapping. In the ﬁnal step of
this iterative procedure, we used our estimated admixture proportions in place of principal components.
We performed admixture mapping using a linear mixed model
(GENESIS) on each ancestral group (African, European, and Native
American) separately [26]. eGFR was the outcome variable. Models
were adjusted for sex, age, study and race/ethnic group (African
American or Hispanic/Latino) and admixture proportions as ﬁxed
effects, and ancestry-adjusted kinship as a random effect. We allowed
for heterogeneous variance within groups deﬁned by study and race.
To account for multiple testing, we used the genome-wide threshold
of p < 5.4 £ 106, estimated using STEAM [23]. As secondary analyses, admixture mapping was conducted separately in the African
American and Hispanic/Latino subjects; signiﬁcance thresholds were
p < 1.6 £ 105 (testing just the African ancestral component) and p <
3.5 £ 106 in the African American and Hispanic/Latino subsets,
respectively.
2.5.3. Estimating ancestry-speciﬁc allele frequencies
We used our local ancestry calls to estimate ancestry-speciﬁc
allele frequencies for loci of interest using the recently developed
method Ancestry-Speciﬁc Allele Frequencies Estimation (ASAFE).
RFMix only infers local ancestry at loci that are present in both the
admixed sequence data and the reference panel, so inferred local
ancestry will not be available at any loci that are not present in SGDP.
However, because local ancestry segments extended over multiple
loci, we can ﬁll in the missing local ancestry calls at a locus of interest
with reasonable conﬁdence by looking at the inferred local ancestry
at neighbouring loci. We can then use the local ancestry calls to estimate the ancestry-speciﬁc allele frequency for each ancestral population at a locus by calculating the frequency of the allele across
haplotypes in our sample with local ancestry assigned to each ancestral population (African, European, and Native American). To account
for uncertainty in the phase of genotypes relative to the local ancestry calls (particularly at loci where local ancestry was not inferred
directly by RFMix), we used the EM algorithm approach implemented
in the ASAFE program [27]. We ran ASAFE using local ancestry calls
for the 9,479 subjects included in our admixture mapping analysis.
2.5.4. Replication
Replication was performed using ancestry-speciﬁc allele frequency information. For East Asian SNVs, we used data from the Rare
Variants for Hypertension in Taiwan Chinese (THRV) study, which
was sequenced in the TOPMed freeze 8 using methods described
above. Additional replication for East Asians were obtained from a
WGS of 1,524 participants (32%, women, mean age 49.5 years, mean
eGFR 102.5 ml/min/1.73 m2) from the BioBank Japan Project (BBJ).
BBJ is a multi-institutional hospital-based study that collaboratively
collected DNA and serum samples from the participants, mainly of
Japanese ancestry, with a diagnosis of any of 47 diseases [28, 29]. Participants on dialysis, and those with serum creatinine level outside of
three times of interquartile range of upper/lower quartile were
excluded. WGS had an average depth of 25.9x as described elsewhere
[30]. Rank-based inverse transformation of the eGFR residuals after
an adjustment for age, sex, and 47 disease affection status was used
as phenotype in single variant and gene-based analyses with an
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adjustment for 20 top principal components as covariates. For the
gene-based analysis for MAF gene in the BBJ, 34 variants comprising
4 nonsynonymous SNVs with FATHMM-MKL score>0.5 or MetaSVM
score>0, and 30 variants within the ﬁrst intron were tested. Burden
test was conducted using rvtest software and SKAT and SKAT-O using
EPACTS software.
For replication of the Amerindian ancestry variant at chromosome
19, we used data from the Hispanic Community Health Study/Study
of Latinos (HCHS/SOL), which was genotyped using a custom Illumina
array and imputed to the TOPMed Freeze 5b multi-ethnic reference
panel. HCHS/SOL analyses were performed among individuals with
higher Amerindian ancestry proportion (Mainland sample, n = 6,767
individuals) [9]. In addition, we attempted to replicate our ﬁndings in
two cohorts of southwest American Indians collected by the Intramural National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) program; namely, participants in a community-based longitudinal study who are predominately of Pima Indian heritage, and
participants from the Family Investigation of Nephropathy and Diabetes (FIND), a study of diabetes and diabetic nephropathy in adults.
The SNV rs539182790 was direct genotyped using Taqman on
Demand in these southwestern American Indian studies and statistical analyses followed the same protocols from TOPMed.

2.5.5. Bioinformatics
We performed a look-up of genomic coordinate overlap (hg38)
in the Roadmap Epigenomics and the Encyclopedia of DNA Elements
(ENCODE) consortium data [31, 32] across different tissues and samples. All datasets included had been released and passed quality control by respective consortia.

5

3. Results
Study design is shown in Fig. 1 and the characteristics of participants in Supp Table 1. The study comprised up to 23,732 TOPMed
participants from 10 multi-ethnic studies and ﬁve racial/ethnic
groups (36% African Americans, 50% European Americans, 9% East
Asians, 5% Hispanics/Latinos and 0.2% American Indians).
3.1. Single variant association results
Single variant analyses included the 23,732 participants, which
were analysed together using a genetic relationship matrix to
account for genetic similarities among subjects. Statistical analyses
accounted for differences in the eGFR distribution observed in these
groups. The quantile-quantile (Q-Q) plot for the WGS analysis is
shown in Supp Fig 1a (genomic control lambda 1.005). Genomewide signiﬁcant associations were identiﬁed on chromosomes 1, 2,
15, 17, and 19 (Figure 2 Figure 3) and. The variants most signiﬁcantly
associated with eGFR were located on chromosomes 1 (rs180996919,
MAF=0.04%, P = 6.1 £ 1011, PVE 0.2%, intronic to PRKAA2), chromosome 2 (rs116951054, MAF=0.09%, P = 4.5 £ 109, PVE 0.1%, intronic
to METTL8) and chromosome 19 (rs539182790, MAF= 0.06%,
P = 3.4 £ 109, PVE 0.1%, intronic to MATK), were all rare and combined explained 0.5% of the trait variance (Table 1). Two variants
overlap epigenomic annotations in tissues from the Roadmap Epigenomics Consortium: rs116951054 (DNAse I hypersensitive sites
[DHS], H3K4me1 kidney) and rs180996919 (DHS, H3K4me1 muscle).
The variants signiﬁcantly associated with eGFR on chromosomes 15
(rs2461702, MAF=0.49, P = 1.2 £ 109, nearest gene GATM) and 17
(rs71147340, MAF=0.34, P = 3.3 £ 109, intronic indel to CDK12)
were previously reported [33]. Conditional analyses on identiﬁed variants did not reveal additional independent associations at the GATM
or CDK12 loci (Supp Fig 2).

2.6. Role of funders

3.2. Gene-based test results

The funders had no role on the study design, execution or interpretation of ﬁndings.

We next tested variants aggregated within genes (n = 16,054
genes) using a burden test that combined all variants in a score test,

Fig. 1. Study design and approaches for discovery, replication and follow-up studies.
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Fig. 2. Manhattan plot for (a) WGS single-variant test, (b) SKAT test, and (c) Burden test. The horizontal line represents the signiﬁcance threshold.
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Fig. 3. Regional plots for signiﬁcant associated loci in single variant analyses. (a) Chromosome 1 locus; (b) Chromosome 2 locus; (c) Chromosome 15 locus; (d) Chromosome 17
locus; (e) Chromosome 19 locus. Each point represents a SNV, plotted with their p-value (on a -log10 scale) as a function of genomic position (NCBI build 38). The index variant is
represented by the purple symbol. The color coding of all other SNPs indicates LD with the index variant in haplotypes inferred from the TOPMed data: red r20.8; gold
0.6  r2<0.8; green 0.4  r2<0.6; cyan 0.2  r2<0.4; blue r2<0.2; gray r2 unknown. The horizontal line represents the signiﬁcance threshold.
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Fig. 3 Continued.

and the SKAT test, which allows for differences in the direction of
effects for rare variants. Q-Q plots are shown in Supp Fig 1b-c,
respectively. Although the burden tests were not signiﬁcant, the
SKAT analyses identiﬁed a signiﬁcant association for the MAF gene,
reﬂecting differences in these approaches for testing rare variants
(Supp Table 2). Sixty-one variants including 32 singletons contributed to the MAF gene-based association in SKAT analysis. To investigate the contribution of single variants to the association at this gene,

we performed single variant association analyses for each variant in
the gene and identiﬁed a missense variant (rs1230233783, p.His191Tyr, AA 191, MAF=0.008) contributing to most of the association with
eGFR (P = 1.27 £ 106). The SKAT analyses using a leave-one-variantout strategy supported the strong contribution of rs1230233783 to
the gene-based association (Figure 4, a-c). This variant also overlaps
epigenomic annotations (H3K27ac ENCODE data). Additional genes
identiﬁed in gene-based analyses are shown in Supp Table 2.

Table 1
Signiﬁcant ﬁndings for single trait genome-wide association of eGFR.
Chr:position (hg38)

SNV/indel

Coded allele/Other

Minor allele
Freq Count

Beta (SE)
(Coded allele)

p

Gene

Function

1:56,690,933
2:171,363,037
15:45,355,229*
17:39,466,919*
19:3,799,817

rs180996919
rs116951054
rs2461702
rs71147340
rs539182790

C/G
A/C
G/A
C/CT
G/GGT

0.0004
0.0009
0.49
0.34
0.0005

14.56 (2.2)
9.10 (1.55)
0.63 (0.10)
0.57 (0.10)
9.69 (1.64)

6.1 £ 1011
4.5 £ 109
1.2 £ 1010
3.3 £ 109
3.4 £ 109

PRKAA2
METTL8
GATM
CDK12
MATK

Intronic
Intronic
Intergenic
Intronic
Intronic

19
41
23,170
16,247
26

SNV, single nucleotide variant. Signiﬁcance threshold 5.0 £ 109; betas are eGFR change in ml/min/1.73 m2 for each additional copy of the coded
allele. Freq, frequency of coded allele.
* Previously reported loci. Regulatory annotation for rs180996919 (DHS, H3K4me1 muscle) and rs116951054 (DHS, H3K4me1 kidney).
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Americans and 1,176 Hispanic/Latinos of 23,732 TOPMed participants
with eGFR (Supp Table 1). The inferred global ancestry proportions
for each African American and Hispanic/Latino individual and the
averages (and ranges) of African, Native American and European
ancestries are shown in Supp Fig 3. These results showed a large variation in ancestry proportions in Hispanics/Latinos in our data. There
were no genome-wide signiﬁcant associations identiﬁed using overall sample (Supp Fig 4) or separately by African American (Supp Fig
5) or Hispanic/Latino ancestry (Supp Fig 6).
Local ancestry calls were used to estimate ancestry-speciﬁc allele
frequencies and rs539182790 allele at MATK was exclusively present
in the Native American ancestral population (MAF = 0.02) and not in
African (MAF = 3.1 £ 1010) or European (MAF = 7.9 £ 104) ancestral
populations (Table 2).
3.4. Replication
Chromosome 1 and 2 variants had higher allele frequencies in
East Asians in the 1000 Genomes Project, so we attempted replication
in two East Asian studies, the THRV study, a cohort of participants
from Taiwan (n = 1,132) and the BBJ, a hospital-based study of 1,524
Japanese (Table 3). Although the p-values were not signiﬁcant, there
was consistent direction of effects between our data and the BBJ
results for rs180996919 and rs116951054. We additionally
attempted replication of the gene-based MAF ﬁndings in BBJ, which
included 34 SNVs but the most inﬂuential missense SNV
rs1230233783 was not avaialble. The gene-based associations were
not signiﬁcant for the burden test (P = 0.99) or SKAT test (P = 0.66).
We also attempted to replicate the Amerindian indel variant on
chromosome 19 (rs539182790) in HCHS/SOL Hispanics/Latinos for
individuals selected for high Amerindian ancestry (Mexican, Central
American, and South American) (n = 6,578, MAF=0.01, P = 0.30), and
among American Indians using several samples: participants of a
community-based study, who are full heritage Pima Indians
(n = 1,438, MAF=0.02, P = 0.86), non-full Pima Indians (n = 757,
MAF=0.01, P = 0.30) and American Indian participants of the FIND
study (about 1/3 Pima Indians and 2/3 other tribes, n = 836,
MAF=0.03, P = 0.74). Although the p-values were not signiﬁcant, the
direction of effects was consistent with TOPMed for full heritage
Pima Indians and HCHS/SOL Hispanic participants (Table 3).
3.5. Trans-ethnic eGFR loci reported in the genome catalog

Fig. 4. Results from single variant analyses for ENSG00000178573 (MAF). (a) Effect
estimates by minor allele count (MAC). (b) Test statistic by MAC. (c) Results from the
leave-one-variant-out analyses at this gene. Note that rs1230233783 is the inﬂuential
SNV in the SKAT gene-based analyses.

3.3. Admixture mapping and estimating ancestry-speciﬁc allele
frequencies
Local ancestry determination and complete phenotype information were available for 9,479 admixed individuals (8,303 African

Among 91 trans-ethnic identiﬁed variants present in our study, 53
were nominally associated with eGFR in our WGS data (including
those reported on chromosomes 15 and 17). The most signiﬁcant
associations of known eGFR loci were for GCKR (P = 2.7 £ 108),
UNCX (P = 3.5 £ 108), VEGFA (P = 1.2 £ 107), PRKAG2
(P = 2.8 £ 107), SHROOM3 (P = 2.6 £ 107), NFATC1 (P = 8.4 £ 107),
MPPED2 (P = 8.9 £ 107), UMOD (P = 1.3 £ 106), CPS1
(P = 4.4 £ 106), LRP2 (P = 3.0 £ 105), RGS14-SLC34A1
(P = 8.6 £ 105) and WDR37 (P = 8.7 £ 105) (Supp Table 3). There
was no evidence of secondary signals at these loci for further ﬁnemapping. We note that there is some overlap of our samples with
published studies.
At the UMOD locus, the most signiﬁcant associated SNV was
rs77924615, an intronic variant of PDILT that has been identiﬁed in
prior trans-ethnic GWAS meta-analyses of eGFR [7] (Supp Fig 7a).
Additional SNVs at the promoter of UMOD have been identiﬁed in
GWAS meta-analyses of eGFR in European ancestry (e.g.
rs12917707). To investigate why SNVs did not achieve genome-wide
signiﬁcance at this widely replicated locus, we compared association
estimates and p-values among European and non-European ancestry
samples, noting that rs12917707 was not in linkage disequilibrium
with rs77924615 in our data (Supp Fig 7b). These SNVs showed
larger variance in estimates in non-European compared to European
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Table 2
Estimated ancestry-speciﬁc allele frequencies for SNVs identiﬁed in single variant test and SKAT WGS analyses using ASAFE.
Chr:position (hg38)

SNV/indel (Gene)

Test

Estimated ancestry-speciﬁc allele frequencies
African

19:3,799,817
16:79,599,332
11:102,593,550
6:44,376,382
17:82,054,634

rs539182790 (MATK)
rs1230233783 (MAF)
rs149589493 (MMP20)
rs190658489 (SPATS1)
rs78902137 (GPS1)

Single variant test
SKAT
SKAT
SKAT
SKAT

European
10

3.1 £ 10
1.4 £ 108
7.4 £ 103
6.6 £ 104
2.6 £ 102

4

7.9 £ 10
4.2 £ 108
2.4 £ 108
3.2 £ 108
2.0 £ 108

Native American
2.2 £ 102
2.0 £ 107
8.9 £ 1011
2.3 £ 107
7.2 £ 1016

SNV, single nucleotide variant. MMP20, SPATS1, GSP1 genes had suggestive association in gene-based SKAT analyses.
rs1230233783 alternative allele is more common in East Asians (see text).

ancestry samples and had lower MAF in non-European compared to
European ancestry data (Supp Table 4).
4. Discussion
This is the largest genetic study addressing a role of low frequency and rare variants on eGFR. Our study used deep coverage
WGS (~38x) from ﬁve ancestral groups for a comprehensive
assessment of SNVs across diverse populations. It also employed
approaches suitable for analyses of rare variants among populations with ancestral admixture. By combining multi-ethnic
groups, we optimised the power to detect low frequency alleles
shared among ethnic groups with admixture, who may carry
ancestry-speciﬁc rare variants. We accounted for recent and
ancestral relatedness in these analyses, and genetic effects that
are heterogeneous across ancestral groups, which are usually not
addressed in GWAS. Lastly, we allowed for heterogeneity in eGFR
distribution observed among ethnic groups, as African Americans
showed larger eGFR trait variance than other groups. Using this
strategy, we identiﬁed ancestry-speciﬁc low frequency variants
inﬂuencing eGFR. We also conﬁrmed associations for common
variants at known loci, although this was not a main goal of this
study. Importantly, our study uncovered several challenges for
the study of rare ancestry-speciﬁc variants including ﬁnding suitable replication samples for validation of associations.
The main ﬁndings are related to 3 rare variants identiﬁed in single
variant analyses, which showed a large effect on decreasing eGFR
(chromosome 1) or increasing eGFR (chromosomes 2 and 19) and
estimates ranging from 10 to 14 ml/min/1.73 m2. However, the PVE
was small for each variant and their joined effects. Two identiﬁed
SNVs more commonly observed in East Asians were located at
PRKAA2 (chromosome 1, rs180996919) and METTL8 (chromosome 2,
rs116951054, intronic). The PRKAA2 SNV in intron 2 of the canonical
mapped transcript (RefSeq NM_006252) is <500 bp 50 to exon 3 of

the gene. PRKAA2 codes for the alpha2 isoform of the AMP-activated
protein kinase (AMPK) subunit and knockdown of AMPKa2 has been
shown to enhance the epithelial-mesenchymal transition, secretion
of inﬂammatory factors, and concomitant ﬁbrosis in proximal tubule
cells in a mouse unilateral ureteral obstruction model, through upregulation of beta-catenin and Smad3 [34]. Based on this empirical
evidence, we hypothesize that the rare allele is leading to down-regulation of the total expression of the gene, or a differential regulation
of a splice form involving the proximal exon. This SNV overlaps DHS
sites in muscle, and it may affect creatinine production instead of kidney function. Little is known about METTL8 but very recent work suggests that this gene is involved in mRNA editing through m3C
epitranscriptomic processes, a potentially new mechanism of renal
gene regulation [35]. Indeed, our functional annotation of the SNV
supported a regulatory function in kidney (H3K4me1 broadPeak, an
enhancer-associated mark in the Roadmap Epigenomics Consortium
data). We were unable to replicate these associations given the paucity of ancestry-speciﬁc WGS samples for East Asians and the low frequency of these variants, with the variants not present in publicly
available GWAS studies.
The chromosome 19 indel rs539182790 is a rare intronic SNV of
the MATK gene. The MATK gene encodes for the megakaryocyteassociated tyrosine kinase, which plays a role in the signal transduction of hematopoietic cells. Our SNV was identiﬁed as an
Amerindian variant based on ancestry-speciﬁc allele frequency analyses. This SNV showed consistent direction of effect in replication
samples of additional Hispanic individuals, and in one of two samples
of southwest American Indians (Full Pima Indians) , although the replication p-values were not signiﬁcant. Given the less known genetic
architecture of American Indians and little relevant reference data for
this population, we cannot rule out that the lack of replication of the
Amerindian SNV is due to differences in ancestral backgrounds of
Hispanic/Latino participants and the southwest American Indians
who were used as replication.

Table 3
Replication ﬁndings for single variant test.
SNV, coded allele (gene)/
Replication study
rs180996919, C (PRKAA2)
THRV
BBJ
rs116951054, A (METTL8)
THRV
BBJ
rs539182790, G (MATK)
HCHS/SOL Hispanics*
Full Pima Indians
Non-Full Pima Indians
FIND American Indians

Number

Minor Allele Count

Beta (SE)

p

Direction of effect consistency

1,113
1,524

4
6

1.317 (2.853)
0.114 (0.305)

0.64
0.71

No
Yes

1,113
1,524

7
4

0.876 (2.039)
0.274 (0.365)

0.67
0.45

No
Yes

6,767
1,438
757
836

201
60
17
56

0.963 (1.059)
0.013 (0.053)
0.080 (0.077)
0.026 (0.076)

0.36
0.81
0.30
0.73

Yes
Yes
No
No

BBJ, BioBank Japan; FIND, Family Investigation of Nephropathy and Diabetes; HCHS/SOL, Hispanic Community Health Study/
Study of Latinos; NA, not available.
* TOPMed freeze 5b imputed data.
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Our ﬁndings also underscore the challenges to study low frequency variants in multi-ethnic studies and admixed populations
when identiﬁed variants are speciﬁc to an ancestral group. Our genebased analyses identiﬁed associations with eGFR at the MAF gene.
MAF encodes a leucine zipper transcription factor, which has a role in
embryological development of kidney cells [36]. The gene is highly
expressed in adult kidney, with transcripts mapping to proximal
tubule cells in healthy human kidney cells [37]. A common variant
near MAF was associated with uric acid levels in East Asians [33] and
it was associated with accelerated eGFR decline among East Asian
diabetic subjects [38]. The most inﬂuential SNV at MAF gene-based
analysis, rs1230233783, is a missense variant with predicted deleterious effects based on multiple annotation algorithms including a Combined Annotation Dependent Depletion (CADD) score of 13.4. This
SNV has both regulatory and coding-effect annotations (H3K27ac
peak in the ENCODE data), and further functional studies are needed
to assess its relevance in the context of human disease genomics.
However, additional studies are needed to conﬁrm our ﬁndings as we
were not able to identify a suitable large sample for replication of the
SNV.
We also identiﬁed differences in allele frequency and a larger variance in effect estimates for two well-replicated UMOD common variants when comparing non-European to European ancestry samples,
which may explain the lack of genome-wide association signiﬁcance
at this locus in our multi-ethnic sample. Allele heterogeneity across
ancestries may also contribute to these ﬁndings.
To our knowledge, this is the ﬁrst multi-ethnic WGS of eGFR. A
prior study from Iceland performed WGS in 2,230 individuals and
imputed sequenced variants into 81,656 chip genotyped individuals
[19]. This study identiﬁed low frequency missense and LoF variants
associated with serum creatinine at the SLC6A19, SLC25A45, SLC47A1,
RNF186 and RNF128 genes. The study was restricted to individuals of
European ancestry. A gene-based analyses of eGFR of variants in the
exome array identiﬁed associations at the SOS2 gene in individuals
mostly of European ancestry [39]. These genes were not signiﬁcant in
our gene-based analyses.
Rare and low frequency variants are more likely to be populationspeciﬁc and their genetic contribution to eGFR variation is mostly
unknown. Our study provides important information for future WGS
studies of rare SNVs for kidney traits, with implications for study
design of SNV discovery and replication, particularly when studying
diverse populations. An important contribution of this study is the
application of a recently developed method to identify suitable replication populations for ancestry-speciﬁc variants identiﬁed in WGS,
for SNVs that may not be available in public repositories and/or have
unknown frequency in populations. Using ASAFE, we used local
ancestry to estimate the allele frequency of our signiﬁcant variants
across populations and determined that the chromosome 19 variant
is Amerindian, while the most common variant at the MAF gene is
more common in East Asians. We expect that this approach will help
to guide replication efforts for WGS studies of complex traits in
multi-ethnic studies or admixed populations. Local ancestry in
admixture mapping approaches could provide additional discovery
when large WGS samples are available in multi-ethnic populations.
In summary, we performed a comprehensive genome-wide discovery study of eGFR in multi-ethnic studies using WGS of over
23,000 individuals that included association and admixture mapping
approaches. We identiﬁed ancestry-speciﬁc low frequency variants
associated with eGFR in both single variant test and gene-based analyses and used estimated local ancestry to guide replication of ﬁndings. Our study exempliﬁes the challenges of studying diverse
populations including ﬁnding suitable replication samples for ancestry-speciﬁc low frequency variants identiﬁed in multi-ethnic studies
and admixed populations. In addition, resources for functional characterization of these identiﬁed WGS rare variants are currently not
available.
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